Michael Dybbs - 05 Jun 2026 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Reporting relationship: Director
Issuer ticker: STRO
Reported as of: 05 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Jun 2026, 16:14:50 UTC
Prior SEC filing: 04 Jun 2026
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ David Pauling as attorney-in-fact

Key filing fact

Michael Dybbs filed Form 4 for SUTRO BIOPHARMA, INC. (STRO) on 09 Jun 2026.

Key facts

This page summarizes Michael Dybbs's Form 4 filing for SUTRO BIOPHARMA, INC. (STRO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 09 Jun 2026, 16:14.

Change

Previous filing in this sequence was filed on 04 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001601264 Primary reporting owner

Dybbs Michael

Relationship: Director
Address: C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Signature: /s/ David Pauling as attorney-in-fact
Signature date: 09 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STRO transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +10,000
Change %
Price: $0.000000^*
Shares after: 10,000
Date: 05 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $26.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option shall vest, subject to the reporting person's provision of service to the issuer on each vesting date, as to 8.33% of the total award monthly, with the first tranche vesting on July 5, 2026, and the award shall be fully vested and exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 5, 2027.